ID   C11B1_HUMAN             Reviewed;         503 AA.
AC   P15538; Q14095; Q4VAQ8; Q4VAQ9; Q9UML2;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 5.
DT   10-MAY-2017, entry version 189.
DE   RecName: Full=Cytochrome P450 11B1, mitochondrial;
DE   AltName: Full=CYPXIB1;
DE   AltName: Full=Cytochrome P-450c11;
DE            Short=Cytochrome P450C11;
DE   AltName: Full=Steroid 11-beta-hydroxylase;
DE            EC=1.14.15.4;
DE   Flags: Precursor;
GN   Name=CYP11B1; Synonyms=S11BH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT CYS-494.
RX   PubMed=2592361;
RA   Mornet E., Dupont J., Vitek A., White P.C.;
RT   "Characterization of two genes encoding human steroid 11 beta-
RT   hydroxylase (P-450(11) beta).";
RL   J. Biol. Chem. 264:20961-20967(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND
RP   VARIANTS GLN-43 AND VAL-386.
RX   PubMed=2401360; DOI=10.1016/0014-5793(90)81190-Y;
RA   Kawamoto T., Mitsuuchi Y., Toda K., Miyahara K., Yokoyama Y.,
RA   Nakao K., Hosoda K., Yamamoto Y., Imura H., Shizuta Y.;
RT   "Cloning of cDNA and genomic DNA for human cytochrome P-45011 beta.";
RL   FEBS Lett. 269:345-349(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-132.
RC   TISSUE=Peripheral blood;
RX   PubMed=7903314; DOI=10.1210/jcem.77.6.7903314;
RA   Naiki Y., Kawamoto T., Mitsuuchi Y., Miyahara K., Toda K., Orii T.,
RA   Imura H., Shizuta Y.;
RT   "A nonsense mutation (TGG [Trp116]-->TAG [Stop]) in CYP11B1 causes
RT   steroid 11 beta-hydroxylase deficiency.";
RL   J. Clin. Endocrinol. Metab. 77:1677-1682(1993).
RN   [8]
RP   PRELIMINARY NUCLEOTIDE SEQUENCE [MRNA] OF 216-466, AND VARIANT
RP   VAL-386.
RX   PubMed=3499608; DOI=10.1073/pnas.84.20.7193;
RA   Chua S.C., Szabo P., Vitek A., Grzeschik K.H., John M., White P.C.;
RT   "Cloning of cDNA encoding steroid 11 beta-hydroxylase (P450c11).";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7193-7197(1987).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-30.
RX   PubMed=1741400; DOI=10.1073/pnas.89.4.1458;
RA   Kawamoto T., Mitsuuchi Y., Toda K., Yokoyama Y., Miyahara K.,
RA   Miura S., Ohnishi T., Icikawa Y., Nakao K., Imura H., Ulick S.,
RA   Shuzuta Y.;
RT   "Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the
RT   biosynthesis of glucocorticoids and mineralocorticoids in humans.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:1458-1462(1992).
RN   [10]
RP   VARIANT AH4 HIS-448.
RX   PubMed=2022736; DOI=10.1172/JCI115182;
RA   White P.C., Dupont J., New M.I., Leiberman E., Hochberg Z.,
RA   Roesler A.;
RT   "A mutation in CYP11B1 (Arg-448-->His) associated with steroid 11
RT   beta-hydroxylase deficiency in Jews of Moroccan origin.";
RL   J. Clin. Invest. 87:1664-1667(1991).
RN   [11]
RP   VARIANTS AH4 SER-42; HIS-133 AND MET-319.
RX   PubMed=9302260; DOI=10.1093/hmg/6.11.1829;
RA   Joehrer K., Geley S., Strasser-Wozak E.M.C., Azziz R., Wollmann H.A.,
RA   Schmitt K., Kofler R., White P.C.;
RT   "CYP11B1 mutations causing non-classic adrenal hyperplasia due to 11
RT   beta-hydroxylase deficiency.";
RL   Hum. Mol. Genet. 6:1829-1834(1997).
RN   [12]
RP   VARIANT CYS-494.
RX   PubMed=10599751; DOI=10.1210/jcem.84.12.6272-6;
RA   Loidi L., Quinteiro C., Barros F., Dominguez F., Barreiro J.,
RA   Pombo M.;
RT   "The C494F variant in the CYP11B1 gene is a sequence polymorphism in
RT   the Spanish population.";
RL   J. Clin. Endocrinol. Metab. 84:4749-4749(1999).
RN   [13]
RP   VARIANTS TYR-10; GLN-43; THR-348 AND VAL-386.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [14]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [15]
RP   VARIANTS GLN-43; ILE-160 AND VAL-293.
RX   PubMed=10391210; DOI=10.1038/10297;
RA   Halushka M.K., Fan J.-B., Bentley K., Hsie L., Shen N., Weder A.,
RA   Cooper R., Lipshutz R., Chakravarti A.;
RT   "Patterns of single-nucleotide polymorphisms in candidate genes for
RT   blood-pressure homeostasis.";
RL   Nat. Genet. 22:239-247(1999).
RN   [16]
RP   VARIANTS AH4 LEU-94; ARG-318 AND HIS-448.
RX   PubMed=16046588; DOI=10.1210/jc.2005-0379;
RA   Grigorescu Sido A., Weber M.M., Grigorescu Sido P., Clausmeyer S.,
RA   Heinrich U., Schulze E.;
RT   "21-Hydroxylase and 11beta-hydroxylase mutations in Romanian patients
RT   with classic congenital adrenal hyperplasia.";
RL   J. Clin. Endocrinol. Metab. 90:5769-5773(2005).
RN   [17]
RP   VARIANT AH4 VAL-379.
RX   PubMed=20331679; DOI=10.1111/j.1399-0004.2010.01403.x;
RA   Kharrat M., Trabelsi S., Chaabouni M., Maazoul F., Kraoua L.,
RA   Ben Jemaa L., Gandoura N., Barsaoui S., Morel Y., M'rad R.,
RA   Chaabouni H.;
RT   "Only two mutations detected in 15 Tunisian patients with 11beta-
RT   hydroxylase deficiency: the p.Q356X and the novel p.G379V.";
RL   Clin. Genet. 78:398-401(2010).
RN   [18]
RP   VARIANTS AH4 SER-42; GLN-43; SER-83; ILE-88; LEU-94; CYS-116; GLY-116;
RP   ARG-125; MET-129; HIS-133; SER-135; LEU-139; PRO-158; LEU-159; VAL-161
RP   DEL; ASP-165; ALA-196; 254-LYS--ALA-259 DEL; ASP-267; PRO-299;
RP   VAL-306; ARG-314; ARG-318; MET-318; PRO-318; MET-319; VAL-321;
RP   VAL-331; SER-341; CYS-366; ASP-368; GLY-371; GLN-374; GLN-384;
RP   GLY-384; VAL-386; ALA-401; HIS-427; PHE-438 DEL; GLY-441; ASP-444;
RP   CYS-448; HIS-448; GLN-453 AND SER-489, AND CHARACTERIZATION OF
RP   VARIANTS AH4 SER-42; GLN-43; SER-83; ILE-88; LEU-94; CYS-116; GLY-116;
RP   ARG-125; MET-129; HIS-133; SER-135; LEU-139; PRO-158; LEU-159;
RP   ASP-165; ALA-196; 254-LYS--ALA-259 DEL; PRO-299; ARG-314; MET-318;
RP   MET-319; VAL-331; CYS-366; ASP-368; GLY-371; GLN-374; GLN-384;
RP   ALA-401; PHE-438 DEL; GLY-441; CYS-448; HIS-448 AND GLN-453.
RX   PubMed=20089618; DOI=10.1210/jc.2009-0651;
RA   Parajes S., Loidi L., Reisch N., Dhir V., Rose I.T., Hampel R.,
RA   Quinkler M., Conway G.S., Castro-Feijoo L., Araujo-Vilar D., Pombo M.,
RA   Dominguez F., Williams E.L., Cole T.R., Kirk J.M., Kaminsky E.,
RA   Rumsby G., Arlt W., Krone N.;
RT   "Functional consequences of seven novel mutations in the CYP11B1 gene:
RT   four mutations associated with nonclassic and three mutations causing
RT   classic 11{beta}-hydroxylase deficiency.";
RL   J. Clin. Endocrinol. Metab. 95:779-788(2010).
RN   [19]
RP   VARIANT AH4 CYS-454.
RX   PubMed=20947076; DOI=10.1016/j.fertnstert.2010.09.035;
RA   Wu C., Zhou Q., Wan L., Ni L., Zheng C., Qian Y., Jin J.;
RT   "Novel homozygous p.R454C mutation in the CYP11B1 gene leads to
RT   11beta-hydroxylase deficiency in a Chinese patient.";
RL   Fertil. Steril. 95:1122-1122(2011).
RN   [20]
RP   VARIANT AH4 ILE-79, AND CHARACTERIZATION OF VARIANT AH4 ILE-79.
RX   PubMed=23940125; DOI=10.1210/jc.2013-1306;
RA   Reisch N., Hoegler W., Parajes S., Rose I.T., Dhir V., Goetzinger J.,
RA   Arlt W., Krone N.;
RT   "A diagnosis not to be missed: nonclassic steroid 11beta-hydroxylase
RT   deficiency presenting with premature adrenarche and hirsutism.";
RL   J. Clin. Endocrinol. Metab. 98:E1620-E1625(2013).
RN   [21]
RP   VARIANTS AH4 LEU-150 AND LEU-463 INS, AND CHARACTERIZATION OF VARIANTS
RP   AH4 LEU-150 AND LEU-463 INS.
RX   PubMed=24536089; DOI=10.1530/EJE-13-0737;
RA   Polat S., Kulle A., Karaca Z., Akkurt I., Kurtoglu S., Kelestimur F.,
RA   Groetzinger J., Holterhus P.M., Riepe F.G.;
RT   "Characterisation of three novel CYP11B1 mutations in classic and non-
RT   classic 11beta-hydroxylase deficiency.";
RL   Eur. J. Endocrinol. 170:697-706(2014).
RN   [22]
RP   VARIANTS AH4 TRP-143; PRO-299; VAL-306; LYS-310 AND GLN-332, AND
RP   CHARACTERIZATION OF VARIANTS AH4 TRP-143; VAL-306; LYS-310 AND
RP   GLN-332.
RX   PubMed=24022297; DOI=10.1038/ejhg.2013.197;
RA   Menabo S., Polat S., Baldazzi L., Kulle A.E., Holterhus P.M.,
RA   Groetzinger J., Fanelli F., Balsamo A., Riepe F.G.;
RT   "Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency:
RT   functional consequences of four CYP11B1 mutations.";
RL   Eur. J. Hum. Genet. 22:610-616(2014).
RN   [23]
RP   VARIANTS AH4 GLN-141; ARG-318 AND HIS-448.
RX   PubMed=24987415; DOI=10.1155/2014/185974;
RA   Dumic K., Yuen T., Grubic Z., Kusec V., Barisic I., New M.I.;
RT   "Two novel CYP11B1 gene mutations in patients from two Croatian
RT   families with 11 beta-hydroxylase deficiency.";
RL   Int. J. Endocrinol. 2014:185974-185979(2014).
RN   [24]
RP   VARIANTS AH4 LEU-42 AND SER-42, AND CHARACTERIZATION OF VARIANTS AH4
RP   LEU-42 AND SER-42.
RX   PubMed=26053152; DOI=10.1111/cen.12834;
RA   Mooij C.F., Parajes S., Rose I.T., Taylor A.E., Bayraktaroglu T.,
RA   Wass J.A., Connell J.M., Ray D.W., Arlt W., Krone N.;
RT   "Characterization of the molecular genetic pathology in patients with
RT   11beta-hydroxylase deficiency.";
RL   Clin. Endocrinol. (Oxf.) 83:629-635(2015).
RN   [25]
RP   VARIANTS AH4 ARG-318; GLY-332 AND HIS-448, AND CHARACTERIZATION OF
RP   VARIANT GLY-332.
RX   PubMed=26476331; DOI=10.1016/j.jsbmb.2015.10.011;
RA   Nguyen H.H., Eiden-Plach A., Hannemann F., Malunowicz E.M.,
RA   Hartmann M.F., Wudy S.A., Bernhardt R.;
RT   "Phenotypic, metabolic, and molecular genetic characterization of six
RT   patients with congenital adrenal hyperplasia caused by novel mutations
RT   in the CYP11B1 gene.";
RL   J. Steroid Biochem. Mol. Biol. 155:126-134(2016).
CC   -!- FUNCTION: Has steroid 11-beta-hydroxylase activity. In addition to
CC       this activity, the 18 or 19-hydroxylation of steroids and the
CC       aromatization of androstendione to estrone have also been ascribed
CC       to cytochrome P450 XIB.
CC   -!- CATALYTIC ACTIVITY: A steroid + 2 reduced adrenodoxin + O(2) + 2
CC       H(+) = an 11-beta- hydroxysteroid + 2 oxidized adrenodoxin +
CC       H(2)O.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000250|UniProtKB:P19099};
CC   -!- SUBCELLULAR LOCATION: Mitochondrion membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P15538-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P15538-2; Sequence=VSP_043308;
CC         Note=No experimental confirmation available.;
CC   -!- DISEASE: Adrenal hyperplasia 4 (AH4) [MIM:202010]: A form of
CC       congenital adrenal hyperplasia, a common recessive disease due to
CC       defective synthesis of cortisol. Congenital adrenal hyperplasia is
CC       characterized by androgen excess leading to ambiguous genitalia in
CC       affected females, rapid somatic growth during childhood in both
CC       sexes with premature closure of the epiphyses and short adult
CC       stature. Four clinical types: 'salt wasting' (SW, the most severe
CC       type), 'simple virilizing' (SV, less severely affected patients),
CC       with normal aldosterone biosynthesis, 'non-classic form' or late-
CC       onset (NC or LOAH) and 'cryptic' (asymptomatic).
CC       {ECO:0000269|PubMed:16046588, ECO:0000269|PubMed:20089618,
CC       ECO:0000269|PubMed:2022736, ECO:0000269|PubMed:20331679,
CC       ECO:0000269|PubMed:20947076, ECO:0000269|PubMed:23940125,
CC       ECO:0000269|PubMed:24022297, ECO:0000269|PubMed:24536089,
CC       ECO:0000269|PubMed:24987415, ECO:0000269|PubMed:26053152,
CC       ECO:0000269|PubMed:26476331, ECO:0000269|PubMed:9302260}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Hyperaldosteronism, familial, 1 (HALD1) [MIM:103900]: A
CC       disorder characterized by hypertension, variable
CC       hyperaldosteronism, and abnormal adrenal steroid production,
CC       including 18-oxocortisol and 18-hydroxycortisol. There is
CC       significant phenotypic heterogeneity, and some individuals never
CC       develop hypertension. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry. The molecular defect
CC       causing hyperaldosteronism familial 1 is an anti-Lepore-type
CC       fusion of the CYP11B1 and CYP11B2 genes. The hybrid gene has the
CC       promoting part of CYP11B1, ACTH-sensitive, and the coding part of
CC       CYP11B2.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M32879; AAA52149.1; -; Genomic_DNA.
DR   EMBL; M32863; AAA52149.1; JOINED; Genomic_DNA.
DR   EMBL; M32878; AAA52149.1; JOINED; Genomic_DNA.
DR   EMBL; X55764; CAA39290.1; -; mRNA.
DR   EMBL; D16153; BAB71992.1; -; Genomic_DNA.
DR   EMBL; D16155; BAA03717.1; -; Genomic_DNA.
DR   EMBL; EU332839; ABY87528.1; -; Genomic_DNA.
DR   EMBL; AC083841; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471162; EAW82293.1; -; Genomic_DNA.
DR   EMBL; BC096286; AAH96286.1; -; mRNA.
DR   EMBL; BC096287; AAH96287.1; -; mRNA.
DR   EMBL; M24667; AAA52148.1; ALT_SEQ; mRNA.
DR   EMBL; D10169; BAA01039.1; -; Genomic_DNA.
DR   CCDS; CCDS34953.1; -. [P15538-2]
DR   CCDS; CCDS6392.1; -. [P15538-1]
DR   PIR; S11338; S11338.
DR   RefSeq; NP_000488.3; NM_000497.3. [P15538-1]
DR   RefSeq; NP_001021384.1; NM_001026213.1. [P15538-2]
DR   UniGene; Hs.184927; -.
DR   ProteinModelPortal; P15538; -.
DR   SMR; P15538; -.
DR   BioGrid; 107956; 1.
DR   STRING; 9606.ENSP00000292427; -.
DR   BindingDB; P15538; -.
DR   ChEMBL; CHEMBL1908; -.
DR   DrugBank; DB04630; Aldosterone.
DR   DrugBank; DB00501; Cimetidine.
DR   DrugBank; DB00257; Clotrimazole.
DR   DrugBank; DB00292; Etomidate.
DR   DrugBank; DB00196; Fluconazole.
DR   DrugBank; DB00741; Hydrocortisone.
DR   DrugBank; DB01026; Ketoconazole.
DR   DrugBank; DB01233; Metoclopramide.
DR   DrugBank; DB01011; Metyrapone.
DR   DrugBank; DB01388; Mibefradil.
DR   DrugBank; DB01110; Miconazole.
DR   DrugBank; DB00648; Mitotane.
DR   DrugBank; DB00252; Phenytoin.
DR   DrugBank; DB00421; Spironolactone.
DR   GuidetoPHARMACOLOGY; 1359; -.
DR   SwissLipids; SLP:000001197; -.
DR   iPTMnet; P15538; -.
DR   PhosphoSitePlus; P15538; -.
DR   BioMuta; CYP11B1; -.
DR   DMDM; 215274267; -.
DR   PaxDb; P15538; -.
DR   PeptideAtlas; P15538; -.
DR   PRIDE; P15538; -.
DR   Ensembl; ENST00000292427; ENSP00000292427; ENSG00000160882. [P15538-1]
DR   Ensembl; ENST00000517471; ENSP00000428043; ENSG00000160882. [P15538-2]
DR   GeneID; 1584; -.
DR   KEGG; hsa:1584; -.
DR   UCSC; uc003yxi.4; human. [P15538-1]
DR   CTD; 1584; -.
DR   DisGeNET; 1584; -.
DR   GeneCards; CYP11B1; -.
DR   HGNC; HGNC:2591; CYP11B1.
DR   HPA; HPA049171; -.
DR   HPA; HPA056348; -.
DR   HPA; HPA057752; -.
DR   MalaCards; CYP11B1; -.
DR   MIM; 103900; phenotype.
DR   MIM; 202010; phenotype.
DR   MIM; 610613; gene.
DR   neXtProt; NX_P15538; -.
DR   OpenTargets; ENSG00000160882; -.
DR   Orphanet; 90795; Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency.
DR   Orphanet; 403; Familial hyperaldosteronism type I.
DR   PharmGKB; PA133; -.
DR   eggNOG; KOG0159; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   GeneTree; ENSGT00760000119243; -.
DR   HOGENOM; HOG000013161; -.
DR   HOVERGEN; HBG051098; -.
DR   InParanoid; P15538; -.
DR   KO; K00497; -.
DR   PhylomeDB; P15538; -.
DR   TreeFam; TF105094; -.
DR   BioCyc; MetaCyc:HS08547-MONOMER; -.
DR   BRENDA; 1.14.15.4; 2681.
DR   Reactome; R-HSA-194002; Glucocorticoid biosynthesis.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   ChiTaRS; CYP11B1; human.
DR   GeneWiki; Steroid_11-beta-hydroxylase; -.
DR   GenomeRNAi; 1584; -.
DR   PRO; PR:P15538; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000160882; -.
DR   CleanEx; HS_CYP11B1; -.
DR   ExpressionAtlas; P15538; baseline and differential.
DR   Genevisible; P15538; HS.
DR   GO; GO:0005743; C:mitochondrial inner membrane; TAS:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0047783; F:corticosterone 18-monooxygenase activity; IBA:GO_Central.
DR   GO; GO:0020037; F:heme binding; IC:BHF-UCL.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0004507; F:steroid 11-beta-monooxygenase activity; IDA:BHF-UCL.
DR   GO; GO:0032342; P:aldosterone biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0006700; P:C21-steroid hormone biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IEP:UniProtKB.
DR   GO; GO:0035865; P:cellular response to potassium ion; IEP:UniProtKB.
DR   GO; GO:0034651; P:cortisol biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0006704; P:glucocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0042593; P:glucose homeostasis; TAS:BHF-UCL.
DR   GO; GO:0006955; P:immune response; TAS:BHF-UCL.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:BHF-UCL.
DR   GO; GO:0016125; P:sterol metabolic process; TAS:Reactome.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002399; Cyt_P450_mitochondrial.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00408; MITP450.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome;
KW   Congenital adrenal hyperplasia; Direct protein sequencing;
KW   Disease mutation; Heme; Iron; Lipid metabolism; Membrane;
KW   Metal-binding; Mitochondrion; Monooxygenase; Oxidoreductase;
KW   Polymorphism; Reference proteome; Steroid metabolism; Steroidogenesis;
KW   Transit peptide.
FT   TRANSIT       1     24       Mitochondrion.
FT   CHAIN        25    503       Cytochrome P450 11B1, mitochondrial.
FT                                /FTId=PRO_0000003596.
FT   METAL       450    450       Iron (heme axial ligand). {ECO:0000250}.
FT   VAR_SEQ     401    466       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_043308.
FT   VARIANT      10     10       C -> Y (in dbSNP:rs6405).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_014145.
FT   VARIANT      42     42       P -> L (in AH4; classic; highly decreases
FT                                steroid 11-beta-hydroxylase activity;
FT                                dbSNP:rs193922538).
FT                                {ECO:0000269|PubMed:26053152}.
FT                                /FTId=VAR_074493.
FT   VARIANT      42     42       P -> S (in AH4; non-classic; highly
FT                                decreases steroid 11-beta-hydroxylase
FT                                activity; dbSNP:rs104894069).
FT                                {ECO:0000269|PubMed:20089618,
FT                                ECO:0000269|PubMed:26053152,
FT                                ECO:0000269|PubMed:9302260}.
FT                                /FTId=VAR_001260.
FT   VARIANT      43     43       R -> Q (in AH4; decreases steroid 11-
FT                                beta-hydroxylase activity; dbSNP:rs4534).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10391210,
FT                                ECO:0000269|PubMed:20089618,
FT                                ECO:0000269|PubMed:2401360}.
FT                                /FTId=VAR_014146.
FT   VARIANT      63     63       D -> H (in dbSNP:rs5282).
FT                                /FTId=VAR_014638.
FT   VARIANT      79     79       F -> I (in AH4; non-classic; highly
FT                                decreases steroid 11-beta-hydroxylase
FT                                activity). {ECO:0000269|PubMed:23940125}.
FT                                /FTId=VAR_074494.
FT   VARIANT      83     83       L -> S (in AH4; highly decreases steroid
FT                                11-beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074495.
FT   VARIANT      88     88       M -> I (in AH4; slightly decreases
FT                                steroid 11-beta-hydroxylase activity;
FT                                dbSNP:rs193922539).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074496.
FT   VARIANT      94     94       P -> L (in AH4; almost abolishes steroid
FT                                11-beta-hydroxylase activity;
FT                                dbSNP:rs104894070).
FT                                {ECO:0000269|PubMed:16046588,
FT                                ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_065666.
FT   VARIANT     116    116       W -> C (in AH4; almost abolishes steroid
FT                                11-beta-hydroxylase activity;
FT                                dbSNP:rs772003869).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074497.
FT   VARIANT     116    116       W -> G (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity;
FT                                dbSNP:rs772733691).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074498.
FT   VARIANT     125    125       H -> R (in AH4; slightly decreases
FT                                steroid 11-beta-hydroxylase activity;
FT                                dbSNP:rs757389720).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074499.
FT   VARIANT     129    129       V -> M (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074500.
FT   VARIANT     133    133       N -> H (in AH4; non-classic; highly
FT                                decreases steroid 11-beta-hydroxylase
FT                                activity; dbSNP:rs104894067).
FT                                {ECO:0000269|PubMed:20089618,
FT                                ECO:0000269|PubMed:9302260}.
FT                                /FTId=VAR_001261.
FT   VARIANT     135    135       P -> S (in AH4; highly decreases steroid
FT                                11-beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074501.
FT   VARIANT     139    139       F -> L (in AH4; decreases steroid 11-
FT                                beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074502.
FT   VARIANT     141    141       R -> Q (in AH4; unknown pathological
FT                                significance; dbSNP:rs267601810).
FT                                {ECO:0000269|PubMed:24987415}.
FT                                /FTId=VAR_075553.
FT   VARIANT     143    143       R -> W (in AH4; non-classic; highly
FT                                decreases steroid 11-beta-hydroxylase
FT                                activity; dbSNP:rs140336749).
FT                                {ECO:0000269|PubMed:24022297}.
FT                                /FTId=VAR_074503.
FT   VARIANT     150    150       S -> L (in AH4; non-classic; highly
FT                                decreases steroid 11-beta-hydroxylase
FT                                activity; dbSNP:rs142484434).
FT                                {ECO:0000269|PubMed:24536089}.
FT                                /FTId=VAR_074504.
FT   VARIANT     158    158       L -> P (in AH4; highly decreases steroid
FT                                11-beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074505.
FT   VARIANT     159    159       P -> L (in AH4; decreases steroid 11-
FT                                beta-hydroxylase activity;
FT                                dbSNP:rs370266763).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074506.
FT   VARIANT     160    160       M -> I (in dbSNP:rs5287).
FT                                {ECO:0000269|PubMed:10391210}.
FT                                /FTId=VAR_014147.
FT   VARIANT     161    161       Missing (in AH4).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074507.
FT   VARIANT     165    165       A -> D (in AH4; almost abolishes steroid
FT                                11-beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074508.
FT   VARIANT     173    173       K -> R (in dbSNP:rs4539).
FT                                /FTId=VAR_014639.
FT   VARIANT     196    196       T -> A (in AH4; decreases steroid 11-
FT                                beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074509.
FT   VARIANT     248    248       T -> I (in dbSNP:rs34620645).
FT                                /FTId=VAR_048462.
FT   VARIANT     254    259       Missing (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074510.
FT   VARIANT     257    257       F -> L (in dbSNP:rs5288).
FT                                /FTId=VAR_014640.
FT   VARIANT     267    267       G -> D (in AH4).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074511.
FT   VARIANT     281    281       S -> N (in dbSNP:rs5291).
FT                                /FTId=VAR_014641.
FT   VARIANT     293    293       L -> V (in dbSNP:rs5292).
FT                                {ECO:0000269|PubMed:10391210}.
FT                                /FTId=VAR_014148.
FT   VARIANT     299    299       L -> P (in AH4; non-classic; almost
FT                                abolishes steroid 11-beta-hydroxylase
FT                                activity; dbSNP:rs387907573).
FT                                {ECO:0000269|PubMed:20089618,
FT                                ECO:0000269|PubMed:24022297}.
FT                                /FTId=VAR_074512.
FT   VARIANT     306    306       A -> V (in AH4; non-classic; almost
FT                                abolishes steroid 11-beta-hydroxylase
FT                                activity; dbSNP:rs387907572).
FT                                {ECO:0000269|PubMed:20089618,
FT                                ECO:0000269|PubMed:24022297}.
FT                                /FTId=VAR_074513.
FT   VARIANT     310    310       E -> K (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity;
FT                                dbSNP:rs387907574).
FT                                {ECO:0000269|PubMed:24022297}.
FT                                /FTId=VAR_074514.
FT   VARIANT     314    314       G -> R (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074515.
FT   VARIANT     318    318       T -> M (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity;
FT                                dbSNP:rs104894061).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_001262.
FT   VARIANT     318    318       T -> P (in AH4).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074516.
FT   VARIANT     318    318       T -> R (in AH4).
FT                                {ECO:0000269|PubMed:16046588,
FT                                ECO:0000269|PubMed:20089618,
FT                                ECO:0000269|PubMed:24987415,
FT                                ECO:0000269|PubMed:26476331}.
FT                                /FTId=VAR_065667.
FT   VARIANT     319    319       T -> M (in AH4; non-classic; decreases
FT                                steroid 11-beta-hydroxylase activity;
FT                                dbSNP:rs104894068).
FT                                {ECO:0000269|PubMed:20089618,
FT                                ECO:0000269|PubMed:9302260}.
FT                                /FTId=VAR_001263.
FT   VARIANT     321    321       F -> V (in AH4).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074517.
FT   VARIANT     331    331       A -> V (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074518.
FT   VARIANT     332    332       R -> G (in AH4; high reduction of steroid
FT                                11-beta-monooxygenase activity).
FT                                {ECO:0000269|PubMed:26476331}.
FT                                /FTId=VAR_075554.
FT   VARIANT     332    332       R -> Q (in AH4; non-classic; highly
FT                                decreases steroid 11-beta-hydroxylase
FT                                activity; dbSNP:rs149881706).
FT                                {ECO:0000269|PubMed:24022297}.
FT                                /FTId=VAR_074519.
FT   VARIANT     341    341       R -> S (in AH4; dbSNP:rs372115638).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074520.
FT   VARIANT     348    348       A -> T (in dbSNP:rs6407).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_014149.
FT   VARIANT     366    366       R -> C (in AH4; decreases steroid 11-
FT                                beta-hydroxylase activity;
FT                                dbSNP:rs773245244).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074521.
FT   VARIANT     368    368       A -> D (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity;
FT                                dbSNP:rs104894071).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074522.
FT   VARIANT     371    371       E -> G (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity;
FT                                dbSNP:rs368944209).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074523.
FT   VARIANT     374    374       R -> Q (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity;
FT                                dbSNP:rs104894062).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_001264.
FT   VARIANT     379    379       G -> V (in AH4).
FT                                {ECO:0000269|PubMed:20331679}.
FT                                /FTId=VAR_065196.
FT   VARIANT     384    384       R -> G (in AH4).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074524.
FT   VARIANT     384    384       R -> Q (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity;
FT                                dbSNP:rs764598023).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074525.
FT   VARIANT     386    386       A -> V (in dbSNP:rs4541).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:20089618,
FT                                ECO:0000269|PubMed:2401360,
FT                                ECO:0000269|PubMed:3499608}.
FT                                /FTId=VAR_014150.
FT   VARIANT     401    401       T -> A (in AH4; decreases steroid 11-
FT                                beta-hydroxylase activity;
FT                                dbSNP:rs201300785).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074526.
FT   VARIANT     404    404       R -> H (in dbSNP:rs4998896).
FT                                /FTId=VAR_048463.
FT   VARIANT     427    427       R -> H (in AH4; dbSNP:rs754432887).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074527.
FT   VARIANT     438    438       Missing (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074528.
FT   VARIANT     439    439       Y -> H (in dbSNP:rs5294).
FT                                /FTId=VAR_014642.
FT   VARIANT     441    441       V -> G (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity;
FT                                dbSNP:rs772169059).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074529.
FT   VARIANT     444    444       G -> D (in AH4; dbSNP:rs779103938).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074530.
FT   VARIANT     448    448       R -> C (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074531.
FT   VARIANT     448    448       R -> H (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity;
FT                                dbSNP:rs28934586).
FT                                {ECO:0000269|PubMed:16046588,
FT                                ECO:0000269|PubMed:20089618,
FT                                ECO:0000269|PubMed:2022736,
FT                                ECO:0000269|PubMed:24987415,
FT                                ECO:0000269|PubMed:26476331}.
FT                                /FTId=VAR_001265.
FT   VARIANT     453    453       R -> Q (in AH4; abolishes steroid 11-
FT                                beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074532.
FT   VARIANT     454    454       R -> C (in AH4).
FT                                {ECO:0000269|PubMed:20947076}.
FT                                /FTId=VAR_065197.
FT   VARIANT     463    463       L -> LL (in AH4; classic; abolishes
FT                                steroid 11-beta-hydroxylase activity).
FT                                {ECO:0000269|PubMed:24536089}.
FT                                /FTId=VAR_074533.
FT   VARIANT     489    489       L -> S (in AH4; dbSNP:rs750428278).
FT                                {ECO:0000269|PubMed:20089618}.
FT                                /FTId=VAR_074534.
FT   VARIANT     494    494       F -> C. {ECO:0000269|PubMed:10599751,
FT                                ECO:0000269|PubMed:2592361}.
FT                                /FTId=VAR_008687.
SQ   SEQUENCE   503 AA;  57573 MW;  0B36D82513960EE9 CRC64;
     MALRAKAEVC MAVPWLSLQR AQALGTRAAR VPRTVLPFEA MPRRPGNRWL RLLQIWREQG
     YEDLHLEVHQ TFQELGPIFR YDLGGAGMVC VMLPEDVEKL QQVDSLHPHR MSLEPWVAYR
     QHRGHKCGVF LLNGPEWRFN RLRLNPEVLS PNAVQRFLPM VDAVARDFSQ ALKKKVLQNA
     RGSLTLDVQP SIFHYTIEAS NLALFGERLG LVGHSPSSAS LNFLHALEVM FKSTVQLMFM
     PRSLSRWTSP KVWKEHFEAW DCIFQYGDNC IQKIYQELAF SRPQQYTSIV AELLLNAELS
     PDAIKANSME LTAGSVDTTV FPLLMTLFEL ARNPNVQQAL RQESLAAAAS ISEHPQKATT
     ELPLLRAALK ETLRLYPVGL FLERVASSDL VLQNYHIPAG TLVRVFLYSL GRNPALFPRP
     ERYNPQRWLD IRGSGRNFYH VPFGFGMRQC LGRRLAEAEM LLLLHHVLKH LQVETLTQED
     IKMVYSFILR PSMFPLLTFR AIN
//
